
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Psychedelics as Medicines: An Emerging New Paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 209-219
Closed Access | Times Cited: 296
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 209-219
Closed Access | Times Cited: 296
Showing 1-25 of 296 citing articles:
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly, Alexandra C. Greb, Lindsay P. Cameron, et al.
Cell Reports (2018) Vol. 23, Iss. 11, pp. 3170-3182
Open Access | Times Cited: 812
Calvin Ly, Alexandra C. Greb, Lindsay P. Cameron, et al.
Cell Reports (2018) Vol. 23, Iss. 11, pp. 3170-3182
Open Access | Times Cited: 812
Predicting Responses to Psychedelics: A Prospective Study
Eline Haijen, Mendel Kaelen, Leor Roseman, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 317
Eline Haijen, Mendel Kaelen, Leor Roseman, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 317
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, et al.
Neuropharmacology (2018) Vol. 142, pp. 143-166
Open Access | Times Cited: 267
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, et al.
Neuropharmacology (2018) Vol. 142, pp. 143-166
Open Access | Times Cited: 267
Potential Therapeutic Effects of Psilocybin
Matthew W. Johnson, Roland R. Griffiths
Neurotherapeutics (2017) Vol. 14, Iss. 3, pp. 734-740
Open Access | Times Cited: 253
Matthew W. Johnson, Roland R. Griffiths
Neurotherapeutics (2017) Vol. 14, Iss. 3, pp. 734-740
Open Access | Times Cited: 253
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
David E. Olson
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 563-567
Open Access | Times Cited: 237
David E. Olson
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 563-567
Open Access | Times Cited: 237
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia‐Romeu, Alan K. Davis, Fire Erowid, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1088-1101
Closed Access | Times Cited: 222
Albert Garcia‐Romeu, Alan K. Davis, Fire Erowid, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1088-1101
Closed Access | Times Cited: 222
Modern Clinical Research on LSD
Matthias E. Liechti
Neuropsychopharmacology (2017) Vol. 42, Iss. 11, pp. 2114-2127
Open Access | Times Cited: 197
Matthias E. Liechti
Neuropsychopharmacology (2017) Vol. 42, Iss. 11, pp. 2114-2127
Open Access | Times Cited: 197
Psychedelics as anti-inflammatory agents
Thomas W. Flanagan, Charles D. Nichols
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 363-375
Closed Access | Times Cited: 197
Thomas W. Flanagan, Charles D. Nichols
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 363-375
Closed Access | Times Cited: 197
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Eduardo Ekman Schenberg
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 187
Eduardo Ekman Schenberg
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 187
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 181
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 181
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Patrick Vizeli, Laura Ley, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 3, pp. 537-544
Open Access | Times Cited: 178
Friederike Holze, Patrick Vizeli, Laura Ley, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 3, pp. 537-544
Open Access | Times Cited: 178
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity
Ido Hartogsohn
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 177
Ido Hartogsohn
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 177
A systematic study of microdosing psychedelics
Vince Polito, Richard J. Stevenson
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0211023-e0211023
Open Access | Times Cited: 175
Vince Polito, Richard J. Stevenson
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0211023-e0211023
Open Access | Times Cited: 175
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 6, pp. 864-871
Open Access | Times Cited: 165
Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 6, pp. 864-871
Open Access | Times Cited: 165
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, et al.
NeuroImage (2020) Vol. 218, pp. 116980-116980
Open Access | Times Cited: 147
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, et al.
NeuroImage (2020) Vol. 218, pp. 116980-116980
Open Access | Times Cited: 147
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
Hannes Kettner, Fernando E. Rosas, Christopher Timmermann, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 143
Hannes Kettner, Fernando E. Rosas, Christopher Timmermann, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 143
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis, et al.
Brain (2021) Vol. 145, Iss. 2, pp. 441-456
Open Access | Times Cited: 142
Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis, et al.
Brain (2021) Vol. 145, Iss. 2, pp. 441-456
Open Access | Times Cited: 142
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
Deepak Cyril D’Souza, Shariful A. Syed, L. Taylor Flynn, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 10, pp. 1854-1862
Open Access | Times Cited: 100
Deepak Cyril D’Souza, Shariful A. Syed, L. Taylor Flynn, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 10, pp. 1854-1862
Open Access | Times Cited: 100
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 4, pp. 557-635
Closed Access | Times Cited: 94
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 4, pp. 557-635
Closed Access | Times Cited: 94
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
David E. Olson
Biochemistry (2022) Vol. 61, Iss. 3, pp. 127-136
Open Access | Times Cited: 76
David E. Olson
Biochemistry (2022) Vol. 61, Iss. 3, pp. 127-136
Open Access | Times Cited: 76
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Marvin M. Urban, Moritz R. Stingl, Marcus W. Meinhardt
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 40
Marvin M. Urban, Moritz R. Stingl, Marcus W. Meinhardt
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 40
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Mehdi Sekssaoui, Joël Bockaert, Philippe Marin, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 4, pp. 747-756
Open Access | Times Cited: 22
Mehdi Sekssaoui, Joël Bockaert, Philippe Marin, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 4, pp. 747-756
Open Access | Times Cited: 22